133 related articles for article (PubMed ID: 38735015)
1. Comparison of rivaroxaban and low molecular weight heparin in the treatment of cancer-associated venous thromboembolism: a Swedish national population-based register study.
Linder M; Ekbom A; Brobert G; Vogtländer K; Balabanova Y; Becattini C; Carrier M; Cohen AT; Coleman CI; Khorana AA; Lee AYY; Psaroudakis G; Abdelgawwad K; Rivera M; Schaefer B; Giunta DH
J Thromb Thrombolysis; 2024 May; ():. PubMed ID: 38735015
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism.
Coleman CI; Caroti KS; Abdelgawwad K; Psaroudakis G; Fatoba S; Rivera M; Schaefer B; Brobert G; Khorana AA; Becattini C; Lee AYY; Ekbom A; Carrier M; Brescia C; Cohen AT
JACC CardioOncol; 2023 Apr; 5(2):189-200. PubMed ID: 37144109
[TBL] [Abstract][Full Text] [Related]
3. Rivaroxaban Versus Low-Molecular-Weight Heparins in a Broad Cohort of Patients With Cancer-Associated Venous Thromboembolism: An Analysis of the OSCAR-US Program.
Caroti KS; Khorana AA; Becattini C; Lee AYY; Ekbom A; Carrier M; Cohen AT; Brescia C; Abdelgawwad K; Psaroudakis G; Rivera M; Schaefer B; Brobert G; Coleman CI
Clin Appl Thromb Hemost; 2023; 29():10760296231189282. PubMed ID: 37583314
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of rivaroxaban compared with low-molecular-weight heparin in cancer-associated thromboembolism.
Costa OS; Kohn CG; Kuderer NM; Lyman GH; Bunz TJ; Coleman CI
Blood Adv; 2020 Sep; 4(17):4045-4051. PubMed ID: 32853381
[TBL] [Abstract][Full Text] [Related]
5. Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy.
Perrotta C; Chahla J; Badariotti G; Ramos J
Cochrane Database Syst Rev; 2022 Aug; 8(8):CD005259. PubMed ID: 35993965
[TBL] [Abstract][Full Text] [Related]
6. Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study.
Woodruff S; Lee AYY; Carrier M; Feugère G; Abreu P; Heissler J
J Thromb Thrombolysis; 2019 May; 47(4):495-504. PubMed ID: 30859370
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the Efficacy and Safety of Rivaroxaban and Low Molecular Heparin in Preventing Venous Thromboembolism in Inpatient Cancer Patients.
Wu S; Guan C; Chang S; Wang C; Zhang J
Ann Pharmacother; 2024 Mar; 58(3):214-222. PubMed ID: 37312538
[TBL] [Abstract][Full Text] [Related]
8. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
[TBL] [Abstract][Full Text] [Related]
9. Recurrent thromboembolism, bleeding, and mortality in Asian patients with venous thromboembolism receiving different oral anticoagulants: A nationwide analysis.
Lee MC; Liao CT; Feng IJ; Yu T; Chang WT; Shih MF; Su HC; Toh HS
Medicine (Baltimore); 2022 Sep; 101(37):e30412. PubMed ID: 36123930
[TBL] [Abstract][Full Text] [Related]
10. Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy.
Perrotta C; Chahla J; Badariotti G; Ramos J
Cochrane Database Syst Rev; 2020 May; 5(5):CD005259. PubMed ID: 32374919
[TBL] [Abstract][Full Text] [Related]
11. Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer.
Lee JH; Oh YM; Lee SD; Lee JS
J Korean Med Sci; 2019 Jun; 34(21):e160. PubMed ID: 31144482
[TBL] [Abstract][Full Text] [Related]
12. Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study.
Stepien K; Nowak K; Zalewski J; Pac A; Undas A
Vascul Pharmacol; 2019 Sep; 120():106567. PubMed ID: 31158568
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
Robertson L; Strachan J
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
[TBL] [Abstract][Full Text] [Related]
14. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials.
Prins MH; Lensing AW; Brighton TA; Lyons RM; Rehm J; Trajanovic M; Davidson BL; Beyer-Westendorf J; Pap ÁF; Berkowitz SD; Cohen AT; Kovacs MJ; Wells PS; Prandoni P
Lancet Haematol; 2014 Oct; 1(1):e37-46. PubMed ID: 27030066
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
[TBL] [Abstract][Full Text] [Related]
16. Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis.
Castellucci LA; Cameron C; Le Gal G; Rodger MA; Coyle D; Wells PS; Clifford T; Gandara E; Wells G; Carrier M
JAMA; 2014 Sep; 312(11):1122-35. PubMed ID: 25226478
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Clinical Outcomes in Patients with Active Cancer Receiving Rivaroxaban or Low-Molecular-Weight Heparin: The OSCAR-UK Study.
Cohen AT; Wallenhorst C; Rivera M; Ay C; Schaefer B; Abdelgawwad K; Psaroudakis G; Brobert G; Ekbom A; Lee AYY; Khorana AA; Becattini C; Carrier M; Coleman CI; Martinez C
Thromb Haemost; 2024 Apr; ():. PubMed ID: 38301711
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficacy and safety of rivaroxaban and low-molecular-weight heparin in Chinese lung cancer patients with nonhigh-risk pulmonary embolism.
Song Y; Yang D; Hou D; She J; Song Y
Thromb J; 2023 Feb; 21(1):16. PubMed ID: 36732741
[TBL] [Abstract][Full Text] [Related]
19. Anticoagulation for the initial treatment of venous thromboembolism in people with cancer.
Kahale LA; Matar CF; Hakoum MB; Tsolakian IG; Yosuico VE; Terrenato I; Sperati F; Barba M; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2021 Dec; 12(12):CD006649. PubMed ID: 34878173
[TBL] [Abstract][Full Text] [Related]
20. Anticoagulation for people with cancer and central venous catheters.
Kahale LA; Tsolakian IG; Hakoum MB; Matar CF; Barba M; Yosuico VE; Terrenato I; Sperati F; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006468. PubMed ID: 29856471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]